La Rosa Holdings Corp. 8-K

What Happened

• La Rosa Holdings Corp. (LRHC) filed an 8‑K reporting amendments dated March 24, 2026 to its November 12, 2025 Securities Purchase Agreement (SPA) and the related Token Right. The SPA originally contemplated up to $250,000,000 of senior secured convertible notes.
• The SPA Amendment changes how net proceeds from future equity lines, equity purchase facilities, or at‑the‑market offerings are allocated and adds reimbursable expense provisions; the Token Right Amendment increases the percentage of tokens an investor is entitled to receive from certain financings.

Key Details

• SPA relates to issuance of senior secured convertible notes with aggregate principal up to $250,000,000 (as previously disclosed).
• Until deferred advisor fees of $751,220.76 are paid, net proceeds from future equity offerings will be allocated: 20% to pay outstanding deferred fees to placement agent/financial advisor, 40% to acquire "Note Purchased Crypto" as a treasury asset, and 40% for general corporate purposes (including working capital, acquisitions, AI data‑center development).
• After those deferred fees are paid, allocation becomes 50% to acquire Note Purchased Crypto and 50% for general corporate purposes; the amendment also contemplates an additional $77,000 deferred fee payable not earlier than December 31, 2026.
• Company agreed to reimburse Buyers and Advisors up to $65,000 for costs and expenses (including legal fees) payable from net proceeds of such equity offerings.
• Token Right Amendment changes token entitlement to: 50% of Tokens purchased with SPA closing proceeds and 56.25% (up from 25%) of Tokens purchased with net proceeds of any "Other Financing."

Why It Matters

• These amendments dictate how future equity financing proceeds will be used, including a substantial portion earmarked to buy crypto as a treasury asset (which will affect the company’s balance sheet composition).
• The Token Right change increases an investor’s claim on tokens issued in certain financings, which could affect token supply allocated to the company versus the investor.
• Investors should note these are amendments to existing financing arrangements (filed on March 24, 2026); other SPA and Token Right terms remain in effect.